Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
|
|
- Chrystal Melton
- 5 years ago
- Views:
Transcription
1 Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman, Department of Medicine University of Mississippi
2 Disclosures Research Support NIH European Union PCORI Industry: Multiple clinical trials Consultant Amgen, Adrenomed, Astra Zeneca, Bayer, Berlin Cures, Bristol Myers Squibb, Boehringer Ingelheim, CVRx, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, Sanofi, SC Pharma, StealthPeptide, Vifor, ZS Pharma
3 Counter-Regulatory Systems Are Also Activated ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; NEP, neutral endopeptidase (neprilysin). 1. Klabunde R. Cardiovascular Physiology Concepts. 2nd ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; Mann DL et al. Braunwald s Heart Disease. 10th ed. Philadelphia, PA: Saunders; Tsutamoto T et al. Circulation. 1997;96: Erdos, Skidgel. FASEB J. 1989;3: Stephenson et al. Biochem J. 1987;241: Kenny et al. Biochem J. 1993;291: Lisy O et al. Am J Physiol. 1998;275:F
4 Counterregulatory Peptide Systems Activated in Heart Failure Patients Prostaglandin Bradykinin These peptides promote vasodilation, salt and water diuresis and have antiremodeling effects that modulate the adverse effects of the RAAS and SNS Adrenomedullin NPs (Natriuretic peptides) Since neprilysin breaks down these peptides, inhibitors of this enzyme should increase their levels and effects in heart failure ANP BNP CNP Urodilatin Dendroaspis ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; NP, natriuretic peptide; NPS, natriuretic peptide system. Mann DL et al. Braunwald s Heart Disease. 10th ed. Philadelphia, PA: Saunders; 2015.
5 ANGIOTENSIN II 1-3 1,2 ANGIOTENSIN RECEPTOR 1-3 VASOCONSTRICTION 1-3 NEPRILYSIN 1,2 sacubitril 1-3 valsartan 2,3 sacubitril/valsartan inhibits neprilysin and blocks the AT1 receptor 3 NATRIURETIC VASODILATION PEPTIDES 1, AT1, angiotensin type 1 receptor. 1. Howell EH, Cameron SJ. Cardiol J. 2016;23(6): Volpe M, et al. Clin Sci. 2016;130(2): ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.
6 PARADIGM-HF Study LCZ696 (Sacubitril/valsartan) in HFrEF Patients Phase III RCT evaluating the efficacy and safety profile of LCZ696 vs enalapril in 8,436 patients with NYHA Class II-IV symptoms, EF <35% and elevated BNP level. Primary endpoint - LCZ696 is superior to enalapril in delaying time to composite of CV mortality and HF hospitalization. PARADIGM-HF was prematurely stopped by the DMC due to evidence that patients receiving LCZ696 lived longer without being hospitalized for heart failure than those who received standard care with ACE-inhibitor enalapril. McMurray JJ, et al. N Engl J Med Sep 11;371(11):
7 PARADIGM-HF: Outcomes McMurray JJ, et al. N Engl J Med Sep 11;371(11):
8 PARADIGM-HF: Prespecified Subgroup Analyses McMurray JJ et al. N Engl J Med 2014
9 25.0 Enalapril HF Readmission Rate After Index HF Hospitalization (%) ENTRESTO 13.4% n=175/1302 OR (95% CI): 0.62 (0.45, 0.87) 9.7% n=104/ % ENTRESTO reduced 30-day readmission by 38% 3.7% ARR Day HF Readmission Data are from a PARADIGM-HF post-hoc analysis (hospital readmission rate was not a primary end point). *The primary unit of analysis was hospitalizations, including repeat hospitalizations, rather than patients. Among patients hospitalized at least once for HF, patient characteristics were similar at baseline between treatment groups. OR, odds ratio. 1. Desai AS, et al. J Am Coll Cardiol. 2016;68(3):
10 Adverse Events During Randomized Treatment EVENT HYPOTENSION Symptomatic Symptomatic with systolic blood pressure <90 mm Hg ELEVATED SERUM CREATININE 2.5 mg/dl 3.0 mg/dl ELEVATED SERUM POTASSIUM > 5.5 mmol/liter > 6.0 mmol/liter Sacubitril/valsartan (N=4187) 588 (14.0) 112 (2.7) 139 (3.3) 63 (1.5) 674 (16.1) 181 (4.3) Enalapril (N=4212) 388 (9.2) 59 (1.4) 188 (4.5) 83 (2.0) 727 (17.3) 236 (5.6) COUGH 474 (11.3) 601 (14.3) ANGIOEDEMA** No treatment or use of antihistamines only Use of catecholamines or glucocorticoids without hospitalization Hospitalization without airway compromise Airway compromise 10 (0.2) 6 (0.1) 3 (0.1) 0 5 (0.1) 4 (0.1) 1 (<0.1) 0 * Shown are results of the analyses of prespecified safety events at any time after randomization. The numbers of patients who permanently discontinued a study drug were as follows: for hypotension, 36 (0.9%) in the LCZ696 group and 29 (0.7%) in the enalapril group (P = 0.38); for renal impairment, 29 (0.7%) and 59 (1.4%), respectively (P = 0.002); and for hyperkalemia, 11 (0.3%) and 15 (0.4%), respectively (P = 0.56). ** Angioedema was adjudicated in a blinded fashion by an expert committee. Adapted from: McMurray JJ, et al. N Engl J Med Sep 11;371(11):
11 FDA-Approved Sacubitril/Valsartan Brand name Indication Dosage Renal/hepatic impairment Switching from an ACE inhibitor Contraindications Side effects Sacubitril/Valsartan Entresto The fixed-dose combination of the neprilysin inhibitor sacubitril and the ARB valsartan is indicated to reduce the risk of CV death and HF hospitalization in patients with HF with reduced ejection fraction. Start with 49/51 mg twice daily. Double the dose after 2 4 weeks, as tolerated, to maintenance dose of 97/103 mg twice daily. For patients not currently taking an ACEI or ARB, or for those with severe renal impairment (egfr <30 ml/min/1.73 m 2 ) or moderate hepatic impairment, start with 24/26 mg twice daily. Stop ACE inhibitor for 36 hours before starting treatment. History of angioedema related to previous ACE inhibitor or ARB, concomitant use of ACE inhibitors, concomitant use of aliskiren in patients with diabetes. WARNING pregnancy, hyperkalemia. Hypotension, hyperkalemia, cough, dizziness, renal failure, and angioedema (0.5% sacubitril/valsartan vs. 0.2% enalapril). Accessed October 20, 2015.
12 COR = class of recommendation; LOR = level of recommendation; ARNI = angiotensin receptor blocker and neprilysin inhibitor. Yancy et al. Circulation. 2016;134(13):e [epub ahead of print] 2016 ACC/AHA/HFSA Heart Failure Guideline Update Pharmacological Treatment for Stage C HFrEF Recommendations for RAS Inhibition with ACE Inhibitor or ARB or ARNI COR LOR Recommendations I I III: Harm III: Harm ACE: A ARB: A ARNI: B-R ARNI: B-R B-R C-EO The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors (Level of Evidence: A), OR ARBs (Level of Evidence: A), OR ARNI (Level of Evidence: B-R) (19) in conjunction with evidence-based beta-blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic HFrEF to reduce morbidity and mortality. In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality. ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. ARNI should not be administered to patients with a history of angioedema.
13 Sacubitril / Valsartan Dose Selection and Titration Equivalent of >10mg Enalapril: Lisinopril >10mg Ramipril >5mg Equivalent of 10mg Enalapril: Lisinopril 10mg Ramipril 5mg STOP ACEi for 36 hours before starting Valsartan/Sacubitril to prevent angioedema Start Valsartan/Sacubitril 49/51mg bid, increase to 97/103mg bid in 2-4 weeks Start Valsartan/Sacubitril 24/26mg bid, increase to 49/51mg bid in 2-4 weeks, and then 97/103mg bid Equivalent of > 160mg Valsartan: Losartan > 50mg Olmesartan > 10mg Equivalent of 160mg Valsartan: Losartan 50mg Olmesartan 10mg Start Valsartan/Sacubitril 49/51mg bid, increase to 97/103mg bid in 2-4 weeks Start Valsartan/Sacubitril 24/26mg bid, increase to 49/51mg bid in 2-4 weeks, and then 97/103mg bid Not currently taking ACEi s or ARB s Start Valsartan/Sacubitril 24/26mg bid, increase to 49/51mg bid in 2-4 weeks, and then 97/103mg bid
14 Impact of Heart Rate on Outcomes in HF 1 1. Castagno D et al. J Am Coll Cardiol. 2012;59:
15 Heart Rate Reduction Through / f Current Inhibition Acts by dose-dependent specific inhibition of I f funny channels that are highly expressed in the SA node. Delayed diastolic depolarization results in HR reduction. In CAD patients with HR>70 bpm, Ivabradine reduced coronary events by 22%, MI by 36% and revascularization by 30%*. Ivabradine has been shown to increases stroke volume, fully preserve myocardial contractility and relaxation, atrioventricular conduction, and ventricular repolarization, and increase blood pressure. Adapted from: Thollon C, et al. Br J Pharmacol. 1994;112:37-42; DiFrancesco A, et al. Drugs. 2004;64: ; Fox K, et al. Lancet Sep 6;372(9641): Ferrari R. Cardiology. 2014;128(2):
16 Ivabradine and Outcomes in Chronic HF: The SHIFT Study Double blind, placebo controlled RCT in symptomatic HF patients in NSR with HR >70 beats/min and EF <0.35. Patients were hospitalized within past year and on stable Rx including a beta blocker, if tolerated. Randomized to ivabradine 7.5 mg bid or placebo. Primary EP was CV death or HF hospitalization. Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
17 Background Rx in Systolic Heart Failure Treatment with the / f Inhibitor Ivabradine Trial (SHIFT) Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
18 Changes in HR Over Time in SHIFT Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
19 Ivabradine Effects on Combined Cardiovascular Mortality and HF Hospitalization Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
20 Ivabradine Effects on Combined Cardiovascular Mortality and HF Hospitalization Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
21 Adverse Events in SHIFT PATIENTS WITH AN ADVERSE EVENT PATIENTS WITH AN ADVERSE EVENT LEADING TO DRUG WITHDRAWAL Ivabradine group (n=3232) Placebo group (n=3260) Ivabradine group (n=3232) Placebo group (n=3260) 2439 (75%) 2423 (74%) All 467 (14%) 416 (13%) 804 (25%) 937 (29%) Heart failure 70 (2%) 82 (3%) 150 (5%) 32 (1%) Symptomatic bradycardia 20 (1%) 5 (<1%) 184 (6%) 48 (1%) Asymptomatic bradycardia 28 (1%) 5 (<1%) 306 (9%) 251 (8%) Atrial fibrillation 135 (4%) 113 (3%) 89 (3%) 17 (1%) Phosphenes 7 (<1%) 3 (<1%) 17 (1%) 7 (<1%) Blurred vision 1 (<1%) 1 (<1%) Adapted from: Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
22 SHIFT: Subgroup Analysis Swedberg K, et al. Lancet.2010 Sep 11;376(9744):
23 FDA-Approved Ivabradine Ivabradine Brand name Indication Dosage Contraindications Side effects Corlanor To reduce the risk of hospitalization for worsening HF in patients with stable, symptomatic chronic HF with LVEF 35% who are in sinus rhythm with resting HR 70 bpm and either are on maximum-tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Start with 5 mg twice daily. After 2 weeks of treatment, adjust dose based on HR. Max is 7.5 mg twice daily. In patients with conduction defects or in whom bradycardia could lead to hemodynamic compromise, start with 2.5 mg twice daily. Acute decompensated HF; BP <90/50 mmhg; sick sinus syndrome or third-degree AV block unless a functioning demand pacemaker is present; resting HR < 60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence. WARNING fetal toxicity. Occurring in 1% of patients are bradycardia, hypertension, atrial fibrillation, and luminous phenomena (phosphenes). Accessed October 20, 2015.
24 2016 ACC/AHA/HFSA Heart Failure Guideline Update Pharmacological Treatment for Stage C HFrEF Recommendation for Ivabradine COR LOR Recommendations IIa B-R Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF 35%) who are receiving GDEM, including a beta-blocker at maximum-tolerated dose and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest (37 40). COR = class of recommendation; LOR = level of recommendation; GDEM = guidelinedirected evaluation and management.
Treating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationREVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2
Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationPharmacology. Update. Learning Objectives. Learning Objectives. for Advanced Practice Nurses
Pharmacology Update for Advanced Practice Nurses Trish Freeman, RPh, PhD Associate Professor, Pharmacy Practice and Science University of Kentucky College of Pharmacy University of Southern Indiana September
More informationPROGRESS AT LAST?: REVIEWING RECENTLY UPDATED ACCF/AHA HEART FAILURE GUIDELINES
PROGRESS AT LAST?: REVIEWING RECENTLY UPDATED ACCF/AHA HEART FAILURE GUIDELINES Jon Linder, Pharm.D. PGY1 Pharmacy Resident Iowa City VA Health Care System Objectives for Pharmacists Summarize the burden
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationNew Medications In the Field of Cardiology
New Medications In the Field of Cardiology Hazal Babadagli, BScPharm, PharmD April 7, 2017 Outline Mechanism of action Evidence behind the medication Implications to disease management Contraindications
More informationPCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS: ARE YOU SURE THESE ARE REALLY CARDIAC DRUGS?
PCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS: ARE YOU SURE THESE ARE REALLY CARDIAC DRUGS? ALLORIE SMITH, PHARM.D. CARDIOVASCULAR UPDATE CONFERENCE FEBRUARY 9, 2012 OBJECTIVES Explain the pharmacology
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationPractical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece
Practical considerations for the use of ARNI in CHF: clinical cases J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Disclosures: Research grants and honoraria for lectures from
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationLCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO Dario Leosco Università di Napoli Federico II Projected changes in cardiovascular diseases CVD Deaths Increase 33% CVD DALYS 22% CAD
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationUpdate in Cardiology What s Hot in 2017?
Update in Cardiology What s Hot in 2017? Mark R. Milunski, MD, FACC, FACP Chief, Cardiology Section Orlando Veterans Affairs Medical Center Associate Professor of Medicine University of Central Florida
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationImproving outcomes in heart failure with reduced EF
Improving outcomes in heart failure with reduced EF Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationInitiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Entresto) Reference Number: CP.PMN.67 Effective Date: 11.01.15 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationGuidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
More informationFeast after Famine: The New Drugs for the Treatment of Heart Failure
Feast after Famine: The New Drugs for the Treatment of Heart Failure Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A., F.E.S.C. Medical Director, Advocate Medical Group-Midwest Heart Specialists Heart Failure
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationDisclosure- J Howlett
Industry Contacts: AstraZeneca, Novartis, Merck, Servier, Pfizer, Medtronic, Abbott Research grants: Servier, CVS, Medtronic, Novartis I am a long serving member of CHEP and CCS HF Guidelines Disclosure-
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION SACUBITRIL/VALSARTAN (Entresto Novartis Pharmaceuticals) Indication: Heart Failure With Reduced Ejection Fraction Recommendation: The Canadian
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationCardiovascular Pharmacotherapy for Heart Failure Management
Cardiovascular Pharmacotherapy for Heart Failure Management AN UPDATE OF THE LATEST RECOMMENDATIONS AND DATA By: Debby Caraballo, PharmD, PhC, BCPS, AQ-Cardiology Balloon Fiesta Symposium, Albuquerque,
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationHeart Failure Pharmacotherapy An Update
Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF
More informationDoes My Patient Always Require Diuretics???
Does My Patient Always Require Diuretics??? Shelley Zieroth, MD Associate Professor, Section of Cardiology Director, SBH Heart Failure and Transplant Clinics Head, Medical Heart Failure Program WRHA Cardiac
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More information